Decreased Abundance of Trefoil Factor 1 Transcript in the Majority of Gastric Carcinomas

Cancer

Volumn 98, Issue 10, 2003, Pages 2184-2191

  Beckler, Andrew D ^a   Roche, James K ^a   Harper, Jeffrey C ^a   Petroni, Gina ^a   Frierson Jr , Henry F ^a   Moskaluk, Christopher A ^a   El Rifai, Wa'el ^a   Powell, Steven M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

DNA sequence; Gastric carcinoma; Immunohistochemistry; Quantitative real time reverse transcriptase polymerase chain reaction (RT PCR); Trefoil factor 1

Indexed keywords

DNA; MESSENGER RNA; TREFOIL FACTOR 1; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CANCER GROWTH; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; STOMACH MUCOSA; TFF1 GENE;

ADENOCARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; PEPTIDES; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 0242526867     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11789     Document Type: Article

References (24)

1. Thim L. Trefoil peptides: from structure to function. Cell Mol Life Sci. 1997;53:888-903.
2. Ribieras S, Tomasetto C, Rio MC. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta. 1998;1378:F61-77.
3. Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol. 2001; 16:319-334.
4. Rio MC, Chenard MP, Wolf C, et al. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology. 1991;100:375-379.
5. Wright NA, Poulsom R, Stamp G, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology. 1993;104:12-20.
6. Bossenmeyer-Pourie C, Kannan R, Ribieras S, et al. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol. 2002;157:761-770.
7. Lefebvre O, Chenard MP, Masson R, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 1996;274:259-262.
8. Tebbutt NC, Giraud AS, Inglese M, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med. 2002;8:1089-1097.
9. Luqmani Y, Bennett C, Paterson I, et al. Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer. 1989;44:806-812.
10. Park WS, Oh RR, Park JY, et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology. 2000;119:691-698.
11. Carvalho R, Kayademir T, Soares P, et al. Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab Invest. 2002; 82:1319-1326.
12. Sakata K, Tamura G, Nishizuka S, et al. Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach. Genes Chromosomes Cancer. 1997;18:318-321.
13. Park WS, Oh RR, Park JY, et al. Mapping of a new target region of allelic loss at 21q22 in primary gastric cancers. Cancer Lett. 2000;159:15-21.
14. Fujimoto J, Yasui W, Tahara H, Tahara E, Kudo Y, Yokozaki H. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett. 2000;149:125-134.
15. McQueen HA, Wyllie AH, Piris J, Foster E, Bird CC. Stability of critical genetic lesions in human colorectal carcinoma xenografts. Br J Cancer. 1991;63:94-96.
16. Hahn SA, Seymour AB, Hoque AT, et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res. 1995;55:4670-4675.
17. El-Rifai W, Smith MF Jr., Li G, et al. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res. 2002;62:4061-4064.
18. Buckhaults P, Rago C, St Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res. 2001;61:6996-7001.
19. Thim L, Madsen F, Poulsen SS. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest. 2002; 32:519-527.
20. Tomasetto C, Masson R, Linares JL, et al. pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology. 2000;118:70-80.
21. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 2002;295: 1726-1729.
22. Kindon H, Pothoulakis C, Thim L, Lynch-Devaney K, Podolsky DK. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology. 1995;109:516-523.
23. Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulsom R, Hanby AM. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci U S A. 1996;93:2137-2142.
24. Torres LF, Karam SM, Wendling C, et al. Trefoil factor 1 (TFF1/pS2) deficiency activates the unfolded protein response. Mol Med. 2002;8:273-282.